Results 51 to 60 of about 21,108 (240)

Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial

Cardiovascular Diabetology, 2022
Background Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) lower blood pressure (BP). When SGLT2i and GLP-1RA are combined, synergistic effects on BP have been observed. The mechanisms underlying
Charlotte C. van Ruiten, Mark M. Smits, Megan D. Kok, Erik H. Serné, Daniël H. van Raalte, Mark H. H. Kramer, Max Nieuwdorp, Richard G. IJzerman   +7 more
doaj   +1 more source

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Comparative efficacy of GLP‐1 RA, tirzepatide and SGLT‐2 inhibitors in metabolic liver disease: A network meta‐analysis

British Journal of Clinical Pharmacology, EarlyView.
Aim Metabolic liver disease, including nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis, is a major cause of chronic liver dysfunction worldwide, creating an urgent need for effective treatments. This systematic literature review (SLR) and network meta‐analysis (NMA) systematically reviews and compares the efficacy and safety ...
Andrej Belančić, Christina Antza, Anastasios Poutachidis, Smaro Palaska, Elvira Meni Maria Gkrinia, Andrea Katrin Faour, Yusuf Ziya Sener, Seher Sener, Rehena Sultana   +8 more
wiley   +1 more source

Dapagliflozin Does Not Protect against Adriamycin-Induced Kidney Injury in Mice

Kidney & Blood Pressure Research
Introduction: Sodium-glucose cotransporter 2 (SGLT2) inhibitors target SGLT2 in renal proximal tubules and promote glycosuria in type 2 diabetes mellitus in humans and animal models, resulting in reduced blood glucose levels.
Jin Joo Cha, Hye-jin Park, Ji Ae Yoo, Jungyeon Ghee, Dae Ryong Cha, Young Sun Kang   +5 more
doaj   +1 more source

Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus

Therapeutic Advances in Endocrinology and Metabolism, 2015
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a novel class of antihyperglycaemic agents with an insulin-independent mode of action. Dapagliflozin is a member of the SGLT2 inhibitors class that has received marketing authorization in Europe and ...
Aris Liakos, Thomas Karagiannis, Eleni Bekiari, Panagiota Boura, Apostolos Tsapas   +4 more
doaj   +1 more source

Dapagliflozin Ameliorates Diabetic Kidney Disease via Upregulating Crry and Alleviating Complement Over-activation in db/db Mice

Frontiers in Pharmacology, 2021
Sodium-glucose cotransporter 2(SGLT2) inhibitors show prominent renal protective effect in diabetic kidney disease (DKD), anti-inflammatory effect being one of its key mechanisms.
Dong-Yuan Chang, Dong-Yuan Chang, Dong-Yuan Chang, Xiao-Qian Li, Xiao-Qian Li, Xiao-Qian Li, Min Chen, Min Chen, Min Chen, Ming-Hui Zhao, Ming-Hui Zhao, Ming-Hui Zhao   +11 more
doaj   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source

IMPACT OF DAPAGLIFLOZIN ON APOPTOSIS AND EFFECTOR CYTOTOXIC CELLS USING BREAST CANCER CELLS IN MICE [PDF]

Bulletin of Pharmaceutical Sciences. Assiut University
Background: Dapagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor with anti-inflammatory, antioxidant, and apoptosis modulator activity.
Shimaa M. Elkhyat, Nageh Elmahdy, Mayada Elhusseiny, Abdel aziz Zidan   +3 more
doaj   +1 more source

Effects of dapagliflozin on the serum levels of fibroblast growth factor 21 and myokines and muscle mass in Japanese patients with type 2 diabetes: A randomized, controlled trial

Journal of Diabetes Investigation, 2020
Aims/Introduction Our aims were to examine the add‐on effects of a sodium–glucose cotransporter 2 inhibitor, dapagliflozin, compared with existing antidiabetes treatments, on anthropometric/metabolic parameters, the levels of an endocrine regulator ...
Hajime Yamakage, Masashi Tanaka, Takayuki Inoue, Shinji Odori, Toru Kusakabe, Noriko Satoh‐Asahara   +5 more
doaj   +1 more source

Dapagliflozin attenuates diabetes-induced diastolic dysfunction and cardiac fibrosis by regulating SGK1 signaling

BMC Medicine, 2022
Background Recent studies have reported improved diastolic function in patients administered sodium-glucose cotransporter 2 inhibitors (SGLT2i). We aimed to investigate the effect of dapagliflozin on left ventricular (LV) diastolic function in a diabetic
Seul-Gee Lee, Darae Kim, Jung-Jae Lee, Hyun-Ju Lee, Ro-kyung Moon, Yong-Joon Lee, Seung-Jun Lee, Oh-Hyun Lee, Choongki Kim, Jaewon Oh, Chan Joo Lee, Yong-ho Lee, Seil Park, Ok-Hee Jeon, Donghoon Choi, Geu-Ru Hong, Jung-Sun Kim   +16 more
doaj   +1 more source